We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmii.2021.02.006 | DOI Listing |
Publication Analysis
Top Keywords
car t-cell
8
t-cell therapy
8
potential role
4
role tocilizumab
4
tocilizumab severe
4
severe gastrointestinal
4
gastrointestinal barrier
4
barrier damage
4
damage car
4
therapy report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!